-
Signature
-
/s/ Matthew Ronsheim
-
Stock symbol
-
INVA
-
Transactions as of
-
Mar 5, 2024
-
Transactions value $
-
$189,988
-
Form type
-
4
-
Date filed
-
3/7/2024, 07:02 PM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
INVA |
Common Stock |
Award |
$190K |
+12.8K |
+45.58% |
$14.88 |
40.8K |
Mar 5, 2024 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
transaction |
INVA |
Non-statutory Stock Option |
Award |
$0 |
+27.3K |
+29.36% |
$0.00 |
120K |
Mar 5, 2024 |
Common Stock |
27.3K |
$14.88 |
Direct |
F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
Dr. Ronsheim is President of Innoviva Specialty Therapeutics, Inc. which is a wholly owned subsidiary of Innoviva Specialty Therapeutics Holdings, LLC, which is a wholly owned subsidiary of Innoviva, Inc.